Efficacy and Safety of Rb‐bFGF in Hair Transplantation: A Prospective and Comparative Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.70464 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Jie Lei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Alopecia, Hair Follicle, Fibroblast Growth Factor 2, Hair. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Air Force Medical University Science and Technology Innovation Talent Navigation Action New Flight Plan, Training Program for Physicians at Xijing Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
This prospective randomized controlled trial aimed to evaluate the clinical value of recombinant bovine basic fibroblast growth factor (rb‐bFGF)‐based combined therapy in hair transplantation, focusing on its optimization effects on follicle survival rate, postoperative hair‐loss dynamics, complication control, and patient satisfaction.
Methods
Sixty patients with moderate‐to‐severe androgenetic alopecia were randomly assigned to either an rb‐bFGF group or a control group. In the rb‐bFGF group, harvested follicles were intraoperatively immersed in an rb‐bFGF–enriched solution and patients received postoperative topical rb‐bFGF gel for 3 weeks, in addition to baseline medications and minoxidil. Control group follicles were stored in saline, with postoperative minoxidil alone. Quantitative assessments include measurements of hair follicle viability and hair density at 3, 6, and 12 months postoperatively. Patient satisfaction was assessed using a three‐level scale, and complication rates were recorded.
Results
The rb‐bFGF group demonstrated superior outcomes compared with controls, including higher 12‐month follicle survival (91.1% vs. 81.0%), lower hair‐loss rate (11.6% vs. 22.7%), greater patient satisfaction (96.7% vs. 80.0%), and fewer complications (20.0% vs. 85.3%). All differences were statistically significant ( p < 0.001).
Conclusion
Intraoperative follicle immersion and postoperative topical application of rb‐bFGF significantly enhance graft survival, reduce early hair loss, decrease complications, and improve overall outcomes in hair transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Medicine, Xi'an PLA Hospital, Xi'an, China.
- Emergency Department, Jiangjin Hospital Affiliated to Chongqing University, Chongqing, China.
Förderung
- Air Force Medical University Science and Technology Innovation Talent Navigation Action New Flight Plan, Training Program for Physicians at Xijing Hospital
- National Natural Science Foundation of China
Zitieren
APA
Lei, J., Xu, X., Wang, Y., An, Z., Liang, Z., & Xue, P. (2025). Efficacy and Safety of Rb‐bFGF in Hair Transplantation: A Prospective and Comparative Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70464
Vancouver
Lei J, Xu X, Wang Y, An Z, Liang Z, Xue P. Efficacy and Safety of Rb‐bFGF in Hair Transplantation: A Prospective and Comparative Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70464
BibTeX
@article{Lei2025,
author = {Lei, Jie and Xu, Xianghao and Wang, Yanping and An, Zhonglian and Liang, Zhen and Xue, Ping},
title = {Efficacy and Safety of Rb‐bFGF in Hair Transplantation: A Prospective and Comparative Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.70464}
}
EUVIMED